Portfolio

Description

ArQule is an American biotechnology company that researches, develops, and commercializes broadly effective cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics. ArQule's discovery efforts are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate), an energy source for cells.